AstraZeneca starts new COVID-19 prevention trials of antibody cocktail.


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ AstraZeneca starts new COVID-19 prevention trials of antibody cocktail.
The Phase III international clinical trial will recruit a total of 5,000 people across countries in Europe and the United States to assess the safety and effectiveness of the antibody cocktail, known as AZD7442.

AstraZeneca started late-stage trials on Saturday of an experimental long-acting monoclonal antibody combination drug it hopes could be used as a so-called prophylactic to prevent COVID-19 infection in at-risk people for up to 12 months.

The Phase III international clinical trial will recruit a total of 5,000 people across countries in Europe and the United States to assess the safety and effectiveness of the antibody cocktail, known as AZD7442.

The prophylactic treatment differs from a vaccine in that it introduces antibodies, rather than prompting the body’s immune system to make them. It may prove useful in people whose immune systems are weaker or compromised, and who don’t respond to vaccination. Separately, AstraZeneca is developing a COVID-19 vaccine in conjunction with researchers at Oxford University.

In Britain, where the trials of the monoclonal antibody combination kicked off on Saturday, 1,000 participants will be recruited at nine sites, researchers leading the UK arm said.

“What we are investigating in this study is whether we can provide protection by giving antibodies that have been shown to neutralize the virus, by injection into the muscle,” said Andrew Ustianowski, a professor and chief investigator on the UK study.

“The hope is that this will then provide good protection for many months against infection.”

Monoclonal antibodies mimic natural antibodies that the body generates to fight off infection. They can be synthesized in the laboratory and are already used to treat some types of cancer.

AstraZeneca said its COVID-19 cocktail - which combines two monoclonal antibodies - has the potential both to treat and prevent disease progression in patients already infected with the SARS-CoV-2 virus and to be given as a preventative medication prior to people such as healthcare workers being exposed to the virus.

“These have been engineered specifically to have what we call a long half-life, (so) we think they will confer protection for (at least) six, but more likely closer to 12 months,” Mene Pangalos, AstraZeneca’s executive vice president of biopharmaceuticals R&D, told reporters at a briefing.

He said this made the cocktail, “in effect, almost like a passive vaccination.”

Alongside the 5,000-participant trial assessing the drug’s potential as a preventative, AstraZeneca also plans to evaluate AZD7442 as a post-exposure preventative and pre-emptive treatment in roughly 1,100 participants in trials in Europe and the United States.

The U.S. government last month awarded $486 million to AstraZeneca to develop and secure supplies of up to 100,000 doses of the COVID-19 cocktail.

The UK government also has an in-principle agreement with AstraZeneca which it says secures access to a million doses of AZD7442 if it is successful in Phase III trials.

Under a plan to set up a global production network, Astra in October enlisted contract manufacturer Lonza to produce the drug in Portsmouth, New Hampshire, starting in the first half of 2021.

Tags : #UnitedStates #Europe #Covid19 #Covid19Infection #Covid19Vaccine #AntibodyCocktail #AstraZeneca #Covid19Cocktail

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

ACT Fibernet Collaborates with Amazon Prime to Offer Prime Lite Benefits to Consumers June 19, 2025
CARE Hospitals Conducts “The Power of 3” Public Awareness Drive at Punjagutta JunctionJune 19, 2025
Legalising key population led health services in Thailand is a gamechangerJune 19, 2025
MGM Healthcare Successfully Performs Rare Endoscopic Skull Base Surgery on a 1-Year-Old with Brain Herniation inside NoseJune 19, 2025
Asian Paints’ Apcolite All Protek redefines the Gold Standard in Interior Paints with Breakthrough ‘Lotus Effect Technology’June 19, 2025
The Soft Touch of Tomorrow: Rural India's Lives Are Being Changed by 3D-Printed LimbsJune 19, 2025
QNET India Celebrates International Yoga Day with Curated Wellness EssentialsJune 18, 2025
illumine Raises $2.5M Seed Funding to Globally Scale Vertical AI Platform for Childcare ManagementJune 18, 2025
Mykare Achieves EBITDA-Positive Status in Elective Surgery Vertical with 80% Revenue GrowthJune 18, 2025
HCG Manavata Cancer Centre Launches Scalp Cooling Therapy To Prevent Chemotherapy-Induced Hair LossJune 18, 2025
Biohacking in India: From Blue Light Glasses to Metabolic TrackingJune 18, 2025
AI-Generated Prescriptions: Will They Ever Be Safe Enough?June 18, 2025
The Role of Panchayats in Public Health: Untapped Potential in Rural GovernanceJune 18, 2025
When Medicines Stop Working: How Communities in India Are Fighting BackJune 18, 2025
Archish Fertility & IVF, India’s First 100% Fully Transparent Fertility Lab, Partners with Amaha Health for Holistic Patient Support & Mental WellbeingJune 17, 2025
Supporting Mental Health in AutismJune 17, 2025
New guidelines for monitoring IBD patients to prevent bowel cancerJune 17, 2025
TTK Prestige Launches Tri-Ply Hexamagic Cookware, Blending Non-Stick Innovation with Triply DurabilityJune 17, 2025
Turning ₹2.35 Crore of Grant into ₹17.9 Crore of Impact: How Villgro-360 ONE’s Capital For Impact is Benefitting Thousands of Marginalised FarmersJune 17, 2025
Online Chikitsa Mitra Rolls Out Mobile App for Specialized, In-Home HealthcareJune 17, 2025